메뉴 건너뛰기




Volumn 7, Issue , 2014, Pages 1971-1977

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

Author keywords

Cutaneous T cell lymphoma; Histone deacetylase inhibitor; Pharmacokinetics

Indexed keywords

BELINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

EID: 84908300263     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S59269     Document Type: Review
Times cited : (20)

References (36)
  • 1
    • 84883620467 scopus 로고    scopus 로고
    • Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma
    • Reimer P, Chawla S. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. J Hematol Oncol. 2013;6:69.
    • (2013) J Hematol Oncol , vol.6 , pp. 69
    • Reimer, P.1    Chawla, S.2
  • 4
    • 84892864994 scopus 로고    scopus 로고
    • Management of T-cell lymphomas: Overcoming challenges and choosing the best treatment
    • Reddy NM, Savani BN. Management of T-cell lymphomas: overcoming challenges and choosing the best treatment. Semin Hematol. 2014;51(1):1-4.
    • (2014) Semin Hematol , vol.51 , Issue.1 , pp. 1-4
    • Reddy, N.M.1    Savani, B.N.2
  • 5
    • 84892854428 scopus 로고    scopus 로고
    • Chemotherapeutic advancements in peripheral T-cell lymphoma
    • Reddy NM, Evens AM. Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin Hematol. 2014;51(1):17-24.
    • (2014) Semin Hematol , vol.51 , Issue.1 , pp. 17-24
    • Reddy, N.M.1    Evens, A.M.2
  • 6
    • 84892855294 scopus 로고    scopus 로고
    • Allogeneic transplantation in T-cell lymphomas
    • Schmitz N, Wu HS, Glass B. Allogeneic transplantation in T-cell lymphomas. Semin Hematol. 2014;51(1):67-72.
    • (2014) Semin Hematol , vol.51 , Issue.1 , pp. 67-72
    • Schmitz, N.1    Wu, H.S.2    Glass, B.3
  • 7
    • 84892838269 scopus 로고    scopus 로고
    • Autologous stem cell transplantation for T-cell lymphomas
    • Giulia P, Corradini P. Autologous stem cell transplantation for T-cell lymphomas. Semin Hematol. 2014;51(1):59-66.
    • (2014) Semin Hematol , vol.51 , Issue.1 , pp. 59-66
    • Giulia, P.1    Corradini, P.2
  • 8
    • 84908319588 scopus 로고    scopus 로고
    • Intensified chemoimmunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
    • Corradini P, Vitolo U, Rambaldi A, et al. Intensified chemoimmunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28(9):1885-1891.
    • (2014) Leukemia , vol.28 , Issue.9 , pp. 1885-1891
    • Corradini, P.1    Vitolo, U.2    Rambaldi, A.3
  • 9
    • 0028791591 scopus 로고
    • Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells
    • Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76(11):2351-2356.
    • (1995) Cancer , vol.76 , Issue.11 , pp. 2351-2356
    • Yamaguchi, M.1    Kita, K.2    Miwa, H.3
  • 10
    • 0036176510 scopus 로고    scopus 로고
    • Mechanisms of cancer drug resistance
    • Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627.
    • (2002) Annu Rev Med , vol.53 , pp. 615-627
    • Gottesman, M.M.1
  • 11
    • 84892945819 scopus 로고    scopus 로고
    • The changing landscape of peripheral T-cell lymphoma in the era of novel therapies
    • Karlin L, Coiff ier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25-34.
    • (2014) Semin Hematol , vol.51 , Issue.1 , pp. 25-34
    • Karlin, L.1    Coiff Ier, B.2
  • 12
    • 65349137584 scopus 로고    scopus 로고
    • Histone deacetylase 1, 2, 6 and acetylated histone H4 in B-and T-cell lymphomas
    • Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B-and T-cell lymphomas. Histopathology. 2009;54(6):688-698.
    • (2009) Histopathology , vol.54 , Issue.6 , pp. 688-698
    • Marquard, L.1    Poulsen, C.B.2    Gjerdrum, L.M.3
  • 13
    • 50049108874 scopus 로고    scopus 로고
    • Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
    • Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008;53(3):267-277.
    • (2008) Histopathology , vol.53 , Issue.3 , pp. 267-277
    • Marquard, L.1    Gjerdrum, L.M.2    Christensen, I.J.3    Jensen, P.B.4    Sehested, M.5    Ralfkiaer, E.6
  • 14
    • 81555228390 scopus 로고    scopus 로고
    • Belinostat: Clinical applications in solid tumors and lymphoma
    • Molife LR, de Bono JS. Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs. 2011;20(12):1723-1732.
    • (2011) Expert Opin Investig Drugs , vol.20 , Issue.12 , pp. 1723-1732
    • Molife, L.R.1    De Bono, J.S.2
  • 15
    • 34248631385 scopus 로고    scopus 로고
    • The role of histone deacetylases (HDACs) in human cancer
    • Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19-25.
    • (2007) Mol Oncol , vol.1 , Issue.1 , pp. 19-25
    • Ropero, S.1    Esteller, M.2
  • 16
    • 34547864236 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Molecular mechanisms of action
    • Xu WS, Par migiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541-5552.
    • (2007) Oncogene , vol.26 , Issue.37 , pp. 5541-5552
    • Xu, W.S.1    Par Migiani, R.B.2    Marks, P.A.3
  • 17
    • 79952977561 scopus 로고    scopus 로고
    • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
    • Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827-5834.
    • (2011) Blood , vol.117 , Issue.22 , pp. 5827-5834
    • Piekarz, R.L.1    Frye, R.2    Prince, H.M.3
  • 18
    • 34547683194 scopus 로고    scopus 로고
    • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
    • Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109-3115.
    • (2007) J Clin Oncol , vol.25 , Issue.21 , pp. 3109-3115
    • Olsen, E.A.1    Kim, Y.H.2    Kuzel, T.M.3
  • 19
    • 84872107995 scopus 로고    scopus 로고
    • Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
    • Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386-394.
    • (2013) Eur J Cancer , vol.49 , Issue.2 , pp. 386-394
    • Duvic, M.1    Dummer, R.2    Becker, J.C.3
  • 20
    • 34547122494 scopus 로고    scopus 로고
    • HDAC inhibitors: Clinical update and mechanism-based potential
    • Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74(5):659-671.
    • (2007) Biochem Pharmacol , vol.74 , Issue.5 , pp. 659-671
    • Glaser, K.B.1
  • 21
    • 84908275043 scopus 로고    scopus 로고
    • BELEODAQ™ (belinostat) for injection [prescribing information], Inc
    • BELEODAQ™ (belinostat) for injection [prescribing information]. Henderson, NV: Spectrum Pharmaceuticals, Inc.; 2014.
    • (2014) Henderson, NV: Spectrum Pharmaceuticals
  • 22
    • 84869869682 scopus 로고    scopus 로고
    • HDAC inhibitor-based therapies: Can we interpret the code?
    • New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6(6):637-656.
    • (2012) Mol Oncol , vol.6 , Issue.6 , pp. 637-656
    • New, M.1    Olzscha, H.2    La Thangue, N.B.3
  • 23
    • 78650848615 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in the treatment of lymphoma
    • Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med. 2010;10(54):462-470.
    • (2010) Discov Med , vol.10 , Issue.54 , pp. 462-470
    • Lemoine, M.1    Younes, A.2
  • 24
    • 13344281000 scopus 로고    scopus 로고
    • Monoclonal antibodies in the treatment of indolent lymphomas
    • Coiffier B. Monoclonal antibodies in the treatment of indolent lymphomas. Best Pract Res Clin Haematol. 2005;18(1):69-80.
    • (2005) Best Pract Res Clin Haematol , vol.18 , Issue.1 , pp. 69-80
    • Coiffier, B.1
  • 25
    • 33845996135 scopus 로고    scopus 로고
    • Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
    • Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31-39.
    • (2007) Blood , vol.109 , Issue.1 , pp. 31-39
    • Duvic, M.1    Talpur, R.2    Ni, X.3
  • 26
    • 51649126841 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
    • Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14(14):4500-4510.
    • (2008) Clin Cancer Res , vol.14 , Issue.14 , pp. 4500-4510
    • Ellis, L.1    Pan, Y.2    Smyth, G.K.3
  • 27
    • 77954504404 scopus 로고    scopus 로고
    • Final results of a Phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]
    • Pohlman B, Advani R, Duvic M, et al. Final results of a Phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]. Blood. 2009;114(22):S379.
    • (2009) Blood , vol.114 , Issue.22 , pp. S379
    • Pohlman, B.1    Advani, R.2    Duvic, M.3
  • 28
    • 84884558230 scopus 로고    scopus 로고
    • Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial
    • (Suppl; absract 8507)
    • O’Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol. 2013;31(Suppl; absract 8507).
    • (2013) J Clin Oncol , vol.31
    • O’connor, O.A.1    Masszi, T.2    Savage, K.J.3
  • 29
    • 67649595236 scopus 로고    scopus 로고
    • Belinostat: A new broad acting antineoplastic histone deacetylase inhibitor
    • Gimsing P. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor. Expert Opin Investig Drugs. 2009;18(4):501-508.
    • (2009) Expert Opin Investig Drugs , vol.18 , Issue.4 , pp. 501-508
    • Gimsing, P.1
  • 30
    • 38949146399 scopus 로고    scopus 로고
    • A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
    • Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008;14(3):804-810.
    • (2008) Clin Cancer Res , vol.14 , Issue.3 , pp. 804-810
    • Steele, N.L.1    Plumb, J.A.2    Vidal, L.3
  • 31
    • 49349104503 scopus 로고    scopus 로고
    • A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
    • Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81(3):170-176.
    • (2008) Eur J Haematol , vol.81 , Issue.3 , pp. 170-176
    • Gimsing, P.1    Hansen, M.2    Knudsen, L.M.3
  • 32
    • 79959611523 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
    • Steele NL, Plumb JA, Vidal L, et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol. 2011;67(6):1273-1279.
    • (2011) Cancer Chemother Pharmacol , vol.67 , Issue.6 , pp. 1273-1279
    • Steele, N.L.1    Plumb, J.A.2    Vidal, L.3
  • 33
    • 67650034421 scopus 로고    scopus 로고
    • A Phase I Study of Oral Belinostat (PXD101) in Patients with Advanced Solid Tumors
    • 2007 ASCO Annual Meeting Proceedings (June 20 Supplement)
    • Kelly WK, Yap T, Lee J, et al. A Phase I Study of Oral Belinostat (PXD101) in Patients with Advanced Solid Tumors. 2007 ASCO Annual Meeting Proceedings. Vol 25, No 18S (June 20 Supplement), 2007:14092.
    • (2007) 2007 ASCO Annual Meeting Proceedings , vol.25 , Issue.18S , pp. 14092
    • Kelly, W.K.1    Yap, T.2    Lee, J.3
  • 34
    • 77955641567 scopus 로고    scopus 로고
    • Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma
    • (Suppl; absract 8580)
    • Zain JM, Foss F, Kelly WK, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol. 2009;27:15S(Suppl; absract 8580).
    • (2009) J Clin Oncol , vol.15S , pp. 27
    • Zain, J.M.1    Foss, F.2    Kelly, W.K.3
  • 35
    • 1642453460 scopus 로고    scopus 로고
    • Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101
    • Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2(8):721-728.
    • (2003) Mol Cancer Ther , vol.2 , Issue.8 , pp. 721-728
    • Plumb, J.A.1    Finn, P.W.2    Williams, R.J.3
  • 36
    • 84908273523 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network, Available at, Accessed August 12
    • National Comprehensive Cancer Network. Non-Hodgkin’s Lymphomas (Version 3.2014). Available at: http://www.nccn.org/professionals/physi-cian_gls/pdf/nhl.pdf. Accessed August 12, 2014.
    • (2014) Non-Hodgkin’s Lymphomas (Version 3.2014)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.